title: [Efficiency of antagonist IVF cycle programming by estrogens].
abstract: OBJECTIVE
  Assess the efficiency of estradiol programming in In Vitro Fertilization (IVF) with antagonists by comparing with classical long luteal agonist protocol.
  
  
  METHODS
  It is a prospective randomized study, comparing 426 cycles in the arm estradiol antagonist with 412 cycles in the arm long agonist. Estradiol 4 mg/day begins on the 25th day of the previous cycle and continues during the menses until the first day of the stimulation which is from Thursday to Sunday whatever the beginning of the menses. The luteal protocol use Decapeptyl 0,1mg which begins on the 20th day of the previous cycle.
  
  
  RESULTS
  Our two populations are similar. No pick-up has been done on Sunday. We have got significantly less oocytes and embryos in estradiol-antagonist (6,8+/-5,3 vs 7,6+/-5,7) and (3,7+/-3,2 vs 4,1+/-3,6) respectively. The ongoing pregnancy rate is comparable in the two groups: 28,6 % for estradiol antagonist 27,9 % for agonist for the whole population and 37 % vs 34,8 % respectively when at least one top embryo was transferred.
  
  
  CONCLUSIONS
  Programming antagonist cycles with estradiol allows the organization of the center; it is easy to implement and seems to give results as good as a long agonist protocol.
authors.affiliation: Clinique mutualiste La Sagesse, Rennes, France. anne.guivarch@wanadoo.fr
authors.forename: A
authors.initials: A
authors.lastname: Guivarc'h-Levêque
authors.forename: P
authors.initials: P
authors.lastname: Arvis
authors.forename: J-L
authors.initials: JL
authors.lastname: Bouchet
authors.forename: P-L
authors.initials: PL
authors.lastname: Broux
authors.forename: L
authors.initials: L
authors.lastname: Moy
authors.forename: G
authors.initials: G
authors.lastname: Priou
authors.forename: J
authors.initials: J
authors.lastname: Vialard
authors.forename: D
authors.initials: D
authors.lastname: Colleu
mesh_terms: D000328:Adult; D004624:Embryo Transfer; D004958:Estradiol / Q000008:administration & dosage*; D004965:Estrogen Antagonists / Q000008:administration & dosage*; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D008186:Luteolytic Agents / Q000008:administration & dosage*; D054315:Oocyte Retrieval; D009865:Oocytes / Q000254:growth & development; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D018873:Pregnancy Rate; D011446:Prospective Studies; D017329:Triptorelin Pamoate / Q000008:administration & dosage*
chemical_list: D004965:Estrogen Antagonists; D008186:Luteolytic Agents; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol